Digoxin Tablet
FDA Label NDC 0904-5921

46 label sections · Submitted to the FDA by Major Pharmaceuticals · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Major Pharmaceuticals for the product Digoxin (NDC 0904-5921). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 heart failure in adults, 1.2 heart failure in pediatric patients, 1.3 atrial fibrillation in adults, 2.1 important dosing and administration information, 2.2 loading dosing regimen in adults and pediatric patients, 2.3 maintenance dosing in adults and pediatric patients over 10 years old, 2.4 maintenance dosing in pediatric patients less than 10 years old, 2.5 monitoring to assess safety, efficacy, and therapeutic blood levels, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Package/Label Display Panel

MAJOR®

NDC 0904-5921-61

Unit Dose

Digoxin

Tablets, USP

125 mcg

100 TABLETS (10 x 10)

Rx only

125mcg Carton Label (935f4e33 109c 448c 822c 530145dbbc05 01)

125mcg Carton Label (935f4e33 109c 448c 822c 530145dbbc05 01)

MAJOR®

NDC 0904-5922-61

Unit Dose

Digoxin

Tablets, USP

250 mcg

100 TABLETS (10 x 10)

Rx only

250mcg Carton Label (935f4e33 109c 448c 822c 530145dbbc05 00)

250mcg Carton Label (935f4e33 109c 448c 822c 530145dbbc05 00)

* Please review the disclaimer below.